Revvity (NYSE:RVTY) Releases Quarterly Earnings Results, Beats Expectations By $0.08 EPS

Revvity (NYSE:RVTY) announced its quarterly earnings data on Tuesday. The company reported $1.38 EPS for the quarter, topping the consensus estimate of $1.30 by $0.08, Zacks reports. The company had revenue of $728.90 million during the quarter, compared to the consensus estimate of $694.73 million. Revvity had a net margin of 8.16% and a return on equity of 8.34%. The company’s quarterly revenue was up 4.3% on a year-over-year basis. During the same quarter last year, the firm posted $1.18 EPS.

Here are the key takeaways from Revvity’s conference call:

• Revvity exceeded expectations in Q3, delivering 7% pro forma organic growth, 29.4% adjusted operating margins, and adjusted EPS of $1.37, $0.08 above the midpoint of its guidance.
• Life sciences organic growth reached 9%, led by high-single-digit reagent growth, mid-single-digit instrument growth, and upper-teens Signals Software growth. Management cited improving pharma and biotech demand, expanding AI-related activity, and growing instrument backlogs, particularly in high-content screening.
• The company raised its full-year outlook to approximately 5% pro forma organic growth and $5.40–$5.45 adjusted EPS, while increasing its operating-margin forecast to 28.8%. Efficiency initiatives and favorable mix are supporting more than 40% incremental margins.
• Diagnostics grew 5% organically, with margins reaching 29.9%; excluding the China immunodiagnostics business targeted for divestiture, margins exceeded 30%. Revvity also launched a type 1 diabetes screening assay in Europe, but reproductive health remains constrained by weak Chinese birth rates.
• Management expects some moderation in Q4 growth, partly because reagent bulk orders shifted into Q3 and Signals Software growth is expected to slow from the high teens to the mid-teens. AI demand is broadening but remains in its early stages, and the company expects no share repurchases in its Q4 guidance.

Revvity Stock Up 11.8%

Shares of RVTY traded up $17.90 during trading hours on Tuesday, reaching $169.50. 1,385,563 shares of the stock traded hands, compared to its average volume of 1,525,091. The company has a current ratio of 1.80, a quick ratio of 1.50 and a debt-to-equity ratio of 0.36. The stock has a fifty day simple moving average of $145.08 and a 200 day simple moving average of $112.36. Revvity has a 52 week low of $81.22 and a 52 week high of $171.74. The company has a market cap of $18.91 billion, a price-to-earnings ratio of 80.55, a PEG ratio of 3.01 and a beta of 1.06.

Revvity Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, February 12th. Investors of record on Friday, January 22nd will be given a dividend of $0.07 per share. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.2%. The ex-dividend date of this dividend is Friday, January 22nd. Revvity’s dividend payout ratio (DPR) is presently 13.33%.

Wall Street Analysts Forecast Growth

RVTY has been the topic of a number of research analyst reports. KeyCorp increased their price objective on shares of Revvity from $125.00 to $165.00 and gave the stock an “overweight” rating in a research report on Friday, September 4th. William Blair began coverage on Revvity in a research report on Monday, October 5th. They issued an “outperform” rating for the company. Evercore reaffirmed an “outperform” rating on shares of Revvity in a research note on Wednesday, August 5th. UBS Group assumed coverage on Revvity in a report on Wednesday, September 9th. They issued a “neutral” rating and a $140.00 price target on the stock. Finally, Royal Bank Of Canada began coverage on Revvity in a research note on Tuesday, September 1st. They issued a “sector perform” rating and a $135.00 price objective for the company. Five research analysts have rated the stock with a Buy rating and thirteen have given a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $124.43.

Insider Transactions at Revvity

In other news, insider Tajinder S. Vohra sold 7,330 shares of the business’s stock in a transaction that occurred on Wednesday, September 16th. The stock was sold at an average price of $140.88, for a total value of $1,032,650.40. Following the transaction, the insider owned 6,635 shares in the company, valued at $934,738.80. The trade was a 52.49% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Maxwell Krakowiak sold 1,631 shares of the company’s stock in a transaction that occurred on Monday, September 21st. The shares were sold at an average price of $144.53, for a total value of $235,728.43. Following the completion of the transaction, the insider directly owned 14,781 shares of the company’s stock, valued at approximately $2,136,297.93. This represents a 9.94% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 9,045 shares of company stock valued at $1,281,439 over the last ninety days. 0.85% of the stock is currently owned by insiders.

Revvity Company Profile

Revvity, Inc provides technology, products and services for the life sciences and diagnostics markets. The company supports pharmaceutical and biotechnology research, clinical laboratories and other healthcare organizations with tools used in drug discovery, biological research, disease detection and laboratory testing.

Its offerings include laboratory instruments, reagents, consumables, software and workflow solutions. Key areas include genomics, proteomics, cellular analysis, imaging, screening, automation and reproductive health, as well as newborn screening and other diagnostic applications.